Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report)'s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.31 and traded as low as $1.16. Fate Therapeutics shares last traded at $1.21, with a volume of 1,845,813 shares changing hands.
Analyst Upgrades and Downgrades
A number of research firms have commented on FATE. Wall Street Zen upgraded Fate Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 15th. Needham & Company LLC reiterated a "hold" rating on shares of Fate Therapeutics in a report on Thursday, June 12th. Robert W. Baird lowered their target price on Fate Therapeutics from $5.00 to $4.00 and set a "neutral" rating for the company in a report on Wednesday, May 14th. Barclays dropped their target price on Fate Therapeutics from $10.00 to $2.00 and set an "overweight" rating for the company in a research report on Wednesday, May 14th. Finally, Stifel Nicolaus reduced their price target on shares of Fate Therapeutics from $5.00 to $3.00 and set a "hold" rating on the stock in a research report on Thursday, March 6th. Eight research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $3.83.
View Our Latest Analysis on Fate Therapeutics
Fate Therapeutics Trading Up 0.8%
The company has a market cap of $138.67 million, a PE ratio of -0.81 and a beta of 2.23. The company has a fifty day simple moving average of $1.22 and a two-hundred day simple moving average of $1.31.
Fate Therapeutics (NASDAQ:FATE - Get Free Report) last released its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.39) by $0.07. Fate Therapeutics had a negative net margin of 1,318.93% and a negative return on equity of 47.17%. The firm had revenue of $1.63 million for the quarter, compared to analyst estimates of $1.18 million. On average, research analysts anticipate that Fate Therapeutics, Inc. will post -1.63 EPS for the current fiscal year.
Institutional Investors Weigh In On Fate Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of FATE. FPC Investment Advisory Inc. purchased a new position in Fate Therapeutics in the fourth quarter valued at $44,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Fate Therapeutics during the 4th quarter worth about $58,000. Monaco Asset Management SAM increased its stake in Fate Therapeutics by 138.0% in the fourth quarter. Monaco Asset Management SAM now owns 327,671 shares of the biopharmaceutical company's stock valued at $541,000 after purchasing an additional 190,000 shares during the last quarter. Intech Investment Management LLC grew its position in shares of Fate Therapeutics by 27.5% in the 4th quarter. Intech Investment Management LLC now owns 39,443 shares of the biopharmaceutical company's stock valued at $65,000 after buying an additional 8,497 shares during the last quarter. Finally, Privium Fund Management B.V. grew its holdings in shares of Fate Therapeutics by 74.0% during the fourth quarter. Privium Fund Management B.V. now owns 87,000 shares of the biopharmaceutical company's stock worth $144,000 after purchasing an additional 37,000 shares during the last quarter. 97.54% of the stock is currently owned by institutional investors and hedge funds.
About Fate Therapeutics
(
Get Free Report)
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fate Therapeutics wasn't on the list.
While Fate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
